Sunday, October 11, 2026

Hippo Holdings ($HIPO): The Insurtech That Stopped Chasing Hype and Started Making Money

Hippo’s insurance platform posted 61% premium growth, a 95.8% combined ratio and a fifth profitable quarter as it shifted toward carrier and MGA fee income.

HIPO $906M

Substack von Philipp Oct 10 8 clicks

Oct 9 HY $573M

Hyster Yale (HY) Multibagger potential as confluence of negatives subside. Attractive after markets part services model

Calvin Blissett 3 clicks

Oct 8 LSAK $405M

Lesaka: A $4.69 Stock With a $20–30 Case

Mispriced Assets 5 clicks

From X

@Fierce__beast Oct 11 1 click

Fierce_beast on X

who is long $woof here? https://t.co/H0SfjxEAjR

@ACapitalLP Oct 11 1 click

A Capital on X

Two event-driven levered equities I’m thinking about this weekend: $XRX and $SVC. $XRX seems simple on paper. Monetize XFS, delever and unlock substantial equity value. But if it’s that obvious, why hasn’t Icahn’s guy done it in eight years? The recent TPG IP monetization suggests they’re willing to get creative, so what’s preventing an XFS transaction? $SVC is potentially more interesting. If the board accepts TKO’s $2bn hotel portfolio offer, you’re creating the remaining net lease portfolio at a very attractive valuation with significant equity torque from deleveraging. My biggest question is whether TKO actually has the financing commitments to close… Thoughts welcome.

@Fierce__beast Oct 11

Fierce_beast on X

$evlv adoption doesn't matter if it's arriving at bad economic terms. anything can be adopted if a company is subsidizing it for example. i care about at whether the adoption is economically profitable and if that economic profit has a long and sustainable runway it doesn't seem like that's the case with $evlv

@Fierce__beast Oct 11

Fierce_beast on X

for $evlv unfortunately it seems the economics of their incremental customer wins are margin dilutive as they are trying to continue growing while competitors are catching up https://t.co/WOBgds8M4K

@ACapitalLP Oct 9 1 click

A Capital on X

$FUBO asymmetric @ $8.85

@stockgutter Oct 9

SG on X

that's 5 halts in the first hour of trading for $CD https://t.co/ur6511hnF4

@stockgutter Oct 9

SG on X

$CD there should be a limit on volatility halts. After 3 or 4 they should just let a ticker trade to where it is going to go.

@StableBread Oct 9

Fajasy on X

At ~$6.8M net of cash, Nubeva Technologies $NBVAF (TSXV: $NBVA) trades below every one of the five small ransomware-security deals I found with a disclosed price. That’s a CAD$13.0M market cap at CAD$0.185/share (70,173,783 × CAD$0.185), or $9.3M at 1.40 USD/CAD, with the $2.49M of cash and $12,262 of debt netted out. The $6.8M buys two granted patents, two pending applications, the unfinished AI decryptor builder, and a deployment agreement with what Nubeva calls a top-10 global bank, on $500,586 of FY2026 revenue. Here’s what larger security firms paid for five small companies that detect, stop, or recover from ransomware, per the buyers’ filings: → Smokescreen (June 2021): Zscaler $ZS paid ~$11.7M in cash for a startup that plants decoys to catch attackers. → TrapX Security (January 2022): Commvault $CVLT paid $18.65M in cash for an Israeli decoy-technology company. → Minerva Labs (March 2023): Rapid7 $RPD paid $34.6M for a 14-person Israeli startup selling anti-evasion and ransomware-prevention software. → Appranix (April 2024): Commvault paid $26.27M in cash and stock for a Boston startup that cuts the time to rebuild cloud applications after an attack. → Airgap Networks (April 2024): Zscaler paid $124.4M for an “early-stage” network-security company whose product it called a “ransomware kill switch.” For context, Commvault bought TrapX and Appranix as product lines already bringing in ~$3.2M and ~$2.4M a year. Rapid7 and Zscaler bought Minerva Labs and Airgap mainly for their technology. A buyer would be paying for Nubeva’s technology too, meaning four AI patents (assuming the last two come through), the key-capture agent, and a top-10 bank as a reference account (if the license customer renewed), not just ~$500K of revenue. Still, Nubeva’s revenue is a fifth or less of what TrapX and Appranix brought in, and 82% of its revenue comes from two customers, one of which may not have renewed. So I’d put a sale at the low end of these deals, $12-19M (Smokescreen to TrapX), or CAD$0.23-0.37/share, 1.3-2.0x from here. The ~$26M median (2.8x) is the more bullish upside case. If nothing works, two more years of burn leave $0.93-1.29M of cash, and adding the two granted patents and what’s left of the business gets shareholders $1.33-2.01M, or CAD$0.03-0.04/share, a 78-86% loss from CAD$0.185. In other words, CAD$0.185 sits ~45% of the way between the CAD$0.03-0.04 floor and a TrapX-size sale (CAD$0.37/share). If those are the only two outcomes, the market is pricing a sale as close to a coin flip.